SARS-CoV-2 pathogenesis

MM Lamers, BL Haagmans - Nature reviews microbiology, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …

The development of COVID-19 treatment

Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)

A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …

[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?

V Bajaj, N Gadi, AP Spihlman, SC Wu, CH Choi… - Frontiers in …, 2021 - frontiersin.org
The novel coronavirus severe acute respiratory syndrome coronavirus 2 causing the
Coronavirus disease (COVID-19) pandemic has ravaged the world with over 72 million total …

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

PW Horby, M Mafham, JL Bell, L Linsell, N Staplin… - The Lancet, 2020 - thelancet.com
Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the
basis of in vitro activity, preclinical studies, and observational studies. Here, we report the …

[HTML][HTML] COVID-19 in early 2021: current status and looking forward

C Wang, Z Wang, G Wang, JYN Lau… - Signal Transduction and …, 2021 - nature.com
Since the first description of a coronavirus-related pneumonia outbreak in December 2019,
the virus SARS-CoV-2 that causes the infection/disease (COVID-19) has evolved into a …

Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update

W Alhazzani, L Evans, F Alshamsi, MH Møller… - Critical care …, 2021 - journals.lww.com
BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions
worldwide. Given the rapidly growing evidence base, we implemented a living guideline …

Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19

N Rosenthal, Z Cao, J Gundrum, J Sianis… - JAMA network …, 2020 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) has infected more than 8.1 million US
residents and killed more than 221 000. There is a dearth of research on epidemiology and …